medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2022, Número 2

<< Anterior Siguiente >>

Medicina & Laboratorio 2022; 26 (2)


Pitiriasis rosada como manifestación dermatológica de infección por SARS-CoV-2: a propósito de un caso

García-Rueda JE, Caicedo-Bolaños AM, Bermúdez-Flórez AM, Baena-Gallego F, Gómez-Ramírez LA, Correa-Ángel AL, Vásquez-Ochoa LA

Idioma: Español
Referencias bibliográficas: 47
Paginas: 177-186
Archivo PDF: 112.46 Kb.


RESUMEN

Las manifestaciones cutáneas relacionadas a la infección por el coronavirus SARS-CoV-2, causante de COVID-19, se han descrito entre el 0,2% y 20,4% de las personas que cursan con esta enfermedad. Las más frecuentemente descritas son: lesiones maculopapulares (47%), lesiones acrales eritematosas con vesículas o pústulas (pseudoperniosis) (19%), urticariales (19%), lesiones vesiculosas (9%) y livedo/necrosis (6%). En particular, la pitiriasis rosada es una dermatosis autolimitada de etiología desconocida, sin embargo, se ha visto asociada a la infección por SARS-CoV-2, con algunos reportes de casos en la literatura. El mecanismo fisiopatológico de las lesiones cutáneas en COVID-19 no es claro, y se han planteado algunas teorías, entre las cuales está el papel que juega la enzima convertidora de angiotensina 2 (ACE2) utilizada por el virus para infectar las células, los infiltrados linfocíticos, los depósitos de factores del complemento en la piel, y la reactivación de virus latentes como los herpes virus humanos. Se presenta el caso de una paciente con pitiriasis rosada asociada a COVID-19 y se describen los casos reportados hasta la fecha.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Litchman G, Nair PA, Le JK J. Pityriasis rosea. TreasureIsland (FL): StatPearls Publishing; 2022. Acceso30 de enero de 2022. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK448091/.

  2. Birlutiu V, Birlutiu RM, Iancu GM. Pityriasisrosea Gibert triggered by SARS-CoV-2 infection:A case report. Medicine (Baltimore)2021;100:e25352. https://doi.org/10.1097/md.0000000000025352.

  3. Elsaie M, Youssef E, Hesham N. Pityriasis rosealikerash as a cutaneous marker for COVID-19infection. J Drugs Dermatol 2020;19:779-780.https://doi.org/10.36849/JDD.2020.5360.

  4. Bostan E, Jarbou A. Atypical pityriasis rosea associatedwith mRNA COVID-19 vaccine. J MedVirol 2021. [Epub ahead of print] 29 de septiembrede 2021. https://doi.org/10.1002/jmv.27364.

  5. Urbina F, Das A, Sudy E. Clinical variants ofpityriasis rosea. World J Clin Cases 2017;5:203-211. https://doi.org/10.12998/wjcc.v5.i6.203.

  6. Paolino G, Di Nicola MR, Cantisani C, MercuriSR. Pityriasis rosea infection in a COVID-19 patientsuccessfully treated with systemic steroidand antihistamine via telemedicine: Literatureupdate of a possible prodromal symptom ofan underlying SARS-CoV-2 infection. DermatolTher 2021;34:e14972. https://doi.org/10.1111/dth.14972.

  7. Ciccarese G, Parodi A, Drago F. SARS-CoV-2as possible inducer of viral reactivations.Dermatol Ther 2020;33:e13878. https://doi.org/10.1111/dth.13878.

  8. Dursun R, Temiz SA. The clinics of HHV-6infection in COVID-19 pandemic: Pityriasisrosea and Kawasaki disease. Dermatol Ther2020;33:e13730. https://doi.org/10.1111/dth.13730.

  9. Neoh CY, Tan AW, Mohamed K, Sun YJ, TanSH. Characterization of the inflammatory cellinfiltrate in herald patches and fully developederuptions of pityriasis rosea. Clin Exp Dermatol2010;35:300-304. https://doi.org/10.1111/j.1365-2230.2009.03469.x.

  10. World Health Organization (WHO). Weeklyepidemiological update on COVID-19-25 January2022. Ginebra, Suiza: World Health Organization;2022. P. 28. Acceso 23 de marzode 2022. Disponible en https://www.who.int/publications/m/item/weekly-epidemiologicalupdate-on-covid-19---22-march-2022.

  11. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y.The epidemiology, diagnosis and treatmentof COVID-19. Int J Antimicrob Agents2020;55:105955. https://doi.org/10.1016/j.ijantimicag.2020.105955.

  12. Sousa-Gonçalves C, Reis-Carreira N, PassosD, Barbosa AL, Baltazar AM, WahnonA, et al. Erythematous papular rash: A dermatologicalfeature of COVID-19. Eur J CaseRep Intern Med 2020;7:001768. https://doi.org/10.12890/2020_001768.

  13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ,He JX, et al. Clinical characteristics of coronavirusdisease 2019 in China. N Engl J Med2020;382:1708-1720. https://doi.org/10.1056/NEJMoa2002032.

  14. Wang CJ, Worswick S. Cutaneous manifestationsof COVID-19. Dermatol OnlineJ 2021;27:13030/qt2m54r7nv. https://doi.org/10.5070/D3271052017.

  15. Zhao Q, Fang X, Pang Z, Zhang B, Liu H,Zhang F. COVID-19 and cutaneous manifestations:a systematic review. J Eur Acad DermatolVenereol 2020;34:2505-2510. https://doi.org/10.1111/jdv.16778.

  16. Andina D, Belloni-Fortina A, Bodemer C, BonifaziE, Chiriac A, Colmenero I, et al. Skin manifestationsof COVID-19 in children: Part 3. ClinExp Dermatol 2021;46:462-472. https://doi.org/10.1111/ced.14483.

  17. Arredondo MI, Gómez LV, Del Río-CobaledaDY. Manifestaciones dermatológicas de COVID-19: ¿casualidad o causalidad? CES Medicina2020;34:34-41. https://doi.org/10.21615/cesmedicina.34.COVID-19.7.

  18. Sameni F, Hajikhani B, Yaslianifard S, GoudarziM, Owlia P, Nasiri MJ, et al. COVID-19 andskin manifestations: An overview of case reports/case series and meta-analysis of prevalencestudies. Front Med (Lausanne) 2020;7:573188.https://doi.org/10.3389/fmed.2020.573188.

  19. Tammaro A, Adebanjo GAR, Parisella FR,Pezzuto A, Rello J. Cutaneous manifestationsin COVID-19: the experiences of Barcelonaand Rome. J Eur Acad Dermatol Venereol

  20. 2020;34:e306-e307. https://doi.org/10.1111/jdv.16530.20. Carrascosa JM, Morillas V, Bielsa I, Munera-Campos M. Cutaneous manifestations in thecontext of SARS-CoV-2 infection (COVID-19).Actas Dermosifiliogr 2020;111:734-742.https://doi.org/10.1016/j.ad.2020.08.002.

  21. Freeman EE, McMahon DE, Lipoff JB, RosenbachM, Kovarik C, Desai SR, et al. Thespectrum of COVID-19-associated dermatologicmanifestations: An international registryof 716 patients from 31 countries. J Am AcadDermatol 2020;83:1118-1129. https://doi.org/10.1016/j.jaad.2020.06.1016.

  22. Galván-Casas C, Català A, Carretero-HernándezG, Rodríguez-Jiménez P, Fernández-NietoD, Rodríguez-Villa Lario A, et al. Classificationof the cutaneous manifestations of COVID-19: arapid prospective nationwide consensus study inSpain with 375 cases. Br J Dermatol 2020;183:71-77. https://doi.org/10.1111/bjd.19163.

  23. Veraldi S, Spigariolo CB. Pityriasis rosea andCOVID-19. J Med Virol 2021;93:4068. https://doi.org/10.1002/jmv.26679.

  24. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad DermatolVenereol 2020;34:e212-213. https://doi.org/10.1111/jdv.16387.

  25. Mohta A, Mohta A, Nai RS, Arora A, JainSK, Mohta A, et al. An observational study ofmucocutaneous manifestations among SARSCoV-2 patients from three COVID-19 dedicatedtertiary care centers. Indian Dermatol OnlineJ 2021;12:687-695. https://doi.org/10.4103/idoj.IDOJ_127_21.

  26. Welsh E, Cardenas-de la Garza JA, Cuellar-Barboza A, Franco-Marquez R, Arvizu-RiveraRI. SARS-CoV-2 spike protein positivity in pityriasisrosea-like and urticaria-like rashes ofCOVID-19. Br J Dermatol 2021;184:1194-1195.https://doi.org/10.1111/bjd.19833.

  27. Andina D, Belloni-Fortina A, Bodemer C, BonifaziE, Chiriac A, Colmenero I, et al. Skinmanifestations of COVID-19 in children: Part 1.Clin Exp Dermatol 2021;46:444-450. https://doi.org/10.1111/ced.14481.

  28. Andina D, Belloni-Fortina A, Bodemer C, BonifaziE, Chiriac A, Colmenero I, et al. Skinmanifestations of COVID-19 in children: Part 2.Clin Exp Dermatol 2021;46:451-461. https://doi.org/10.1111/ced.14482.

  29. Drago F, Ciccarese G, Rebora A, Parodi A.Human herpesvirus-6, -7, and Epstein-Barrvirus reactivation in pityriasis rosea duringCOVID-19. J Med Virol 2021;93:1850-1851.https://doi.org/10.1002/jmv.26549.

  30. Broccolo F, Drago F, Careddu AM, FoglieniC, Turbino L, Cocuzza CE, et al. Additionalevidence that pityriasis rosea is associated withreactivation of human herpesvirus-6 and -7. J InvestDermatol 2005;124:1234-1240. https://doi.org/10.1111/j.0022-202X.2005.23719.x.

  31. Müller JA, Groß R, Conzelmann C, KrügerJ, Merle U, Steinhart J, et al. SARS-CoV-2infects and replicates in cells of the humanendocrine and exocrine pancreas. Nat Metab2021;3:149-165. https://doi.org/10.1038/s42255-021-00347-1.

  32. Ndeupen S, Bouteau A, Herbst C, Qin Z, HutchinsZ, Kurup D, et al. Langerhans cells andcDC1s play redundant roles in mRNA-LNP inducedprotective anti-influenza and anti-SARSCoV-2 responses. bioRxiv 2021. https://doi.org/10.1101/2021.08.01.454662.

  33. Veraldi S, Romagnuolo M, Benzecry V. Pityriasisrosea-like eruption revealing COVID-19. AustralasJ Dermatol 2021;62:e333-334. https://doi.org/10.1111/ajd.13504.

  34. Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis roseaas a cutaneous manifestation of COVID-19infection. J Eur Acad Dermatol Venereol2020;34:e436-437. https://doi.org/10.1111/jdv.16579.

  35. Martín-Enguix D, Salazar-Nievas MDC, Martín-Romero DT. Pityriasis rosea Gibert type rashin an asymptomatic patient that tested positivefor COVID-19. Med Clin (Engl Ed) 2020;155:273.https://doi.org/10.1016/j.medcle.2020.05.017.

  36. Sanchez A, Sohier P, Benghanem S,L'Honneur AS, Rozenberg F, Dupin N, etal. Digitate papulosquamous eruption associatedwith severe acute respiratory syndromecoronavirus 2 infection. JAMA Dermatol2020;156:819-820. https://doi.org/10.1001/jamadermatol.2020.1704.

  37. Merhy R, Sarkis AS, Stephan F. Pityriasis roseaas a leading manifestation of COVID-19infection. J Eur Acad Dermatol Venereol2021;35:e246-247. https://doi.org/10.1111/jdv.17052.

  38. Johansen M, Chisolm SS, Aspey LD, BrahmbhattM. Pityriasis rosea in otherwise asymptomaticconfirmed COVID-19-positive patients: Areport of 2 cases. JAAD Case Rep 2021;7:93-94.https://doi.org/10.1016/j.jdcr.2020.10.035.

  39. Ng SM. Prolonged dermatological manifestation4 weeks following recovery of COVID-19in a child. BMJ Case Rep 2020;13:e237056.https://doi.org/10.1136/bcr-2020-237056.

  40. Duong TA, Velter C, Rybojad M, Comte C, BagotM, Sulimovic L, et al. Did Whatsapp(®) reveala new cutaneous COVID-19 manifestation?J Eur Acad Dermatol Venereol 2020;34:e348-350. https://doi.org/10.1111/jdv.16534.

  41. Gambichler T, Boms S, Susok L, Dickel H, FinisC, Abu-Rached N, et al. Cutaneous findings followingCOVID-19 vaccination: review of worldliterature and own experience. J Eur Acad DermatolVenereol 2022;36:172-180. https://doi.org/10.1111/jdv.17744.

  42. Pedrazini MC, da Silva MH. Pityriasis rosea-likecutaneous eruption as a possible dermatologicalmanifestation after Oxford-AstraZenecavaccine: Case report and brief literature review.Dermatol Ther 2021;34:e15129. https://doi.org/10.1111/dth.15129.

  43. McMahon DE, Amerson E, Rosenbach M, LipoffJB, Moustafa D, Tyagi A, et al. Cutaneousreactions reported after Moderna and PfizerCOVID-19 vaccination: A registry-based studyof 414 cases. J Am Acad Dermatol 2021;85:46-55. https://doi.org/10.1016/j.jaad.2021.03.092.

  44. Català A, Muñoz-Santos C, Galván-Casas C,Roncero-Riesco M, Revilla-Nebreda D, Solá-Truyols A, et al. Cutaneous reactions afterSARS-CoV-2 vaccination: a cross-sectional Spanishnationwide study of 405 cases. Br J Dermatol2022;186:142-152. https://doi.org/10.1111/bjd.20639.

  45. McMahon DE, Kovarik CL, Damsky W, RosenbachM, Lipoff JB, Tyagi A, et al. Clinicaland pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP:A registry-based study. J Am Acad Dermatol2022;86:113-121. https://doi.org/10.1016/j.jaad.2021.09.002.

  46. Temiz SA, Abdelmaksoud A, Dursun R, DurmazK, Sadoughifar R, Hasan A. Pityriasis roseafollowing SARS-CoV-2 vaccination: A caseseries. J Cosmet Dermatol 2021;20:3080-3084.https://doi.org/10.1111/jocd.14372.

  47. Leerunyakul K, Pakornphadungsit K, SuchonwanitP. Case report: pityriasis rosea-likeeruption following COVID-19 vaccination. FrontMed (Lausanne) 2021;8:752443. https://doi.org/10.3389/fmed.2021.752443.




2020     |     www.medigraphic.com